Study of PJ009 for short bowel syndrome patients needing IV nutrition
Part of Digestive system clinical trials.
This trial tests a new medicine called PJ009 for people with short bowel syndrome who need intravenous (IV) nutrition support. It aims to help reduce the need for IV nutrition. To join, you must have been dependent on IV nutrition for at least six months and be on a stable schedule.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 14 years old.
- You must have short bowel syndrome and need IV nutrition at least 3 times a week for the past 6 months or more.
- Your IV nutrition schedule must have been stable for at least 4 weeks before starting the study.
- If you have Crohn's disease, it must be in remission (no symptoms) for at least 12 weeks.
- You must not have taken certain related medicines like teduglutide, GLP-2 analogs, human growth hormone, or others recently (check with your doctor).
- You must not have active infections, cancer (except certain treated ones), or severe liver, kidney, or pancreas problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called teduglutide for adults in China with short bowel syndrome who need long-term IV nutrition or fluids (parenteral support). The goal is to see if teduglutide can help them reduce or stop the need for these IV treatments.
This trial tests a new medication called glepaglutide to see if it can help people with short bowel syndrome (SBS) who need IV nutrition or fluids at least 3 days a week. The goal is to reduce or even stop the need for these IV treatments.
This Phase 2 study tests whether sonefpeglutide is safe and how the body handles it (pharmacokinetics) in people with short bowel syndrome. It may help people who still need nutrition through a tube because their intestinal condition is stable.
This study tests a new treatment called FT1 for people with short bowel syndrome. It aims to help you absorb more nutrients and fluids from food, potentially reducing the need for IV nutrition.
This trial tests if crofelemer can reduce diarrhea and fluid loss in people with short bowel syndrome who have a stoma (no colon connection) and need intravenous nutrition or fluids. The goal is to see if it improves gut function and quality of life.
This trial studies whether the Eclipse XL1 system is safe and may help people with short bowel syndrome, in both children and adults. It will check how well the approach works and watch for side effects over the study period.
Hear when a new Short Bowel Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.